Market watch: Sales from licensed and acquired products to increase by 2013

@article{Goodman2009MarketWS,
  title={Market watch: Sales from licensed and acquired products to increase by 2013},
  author={Michael L. Goodman},
  journal={Nature Reviews Drug Discovery},
  year={2009},
  volume={8},
  pages={443-443}
}
AVos Life sciences has analysed the revenue contribution of organically developed, licensed or co-developed, acquired and joint venture products to the major rx drug portfolios (MrDPs: the collection of branded drugs that are each predicted to generate at least us$500 million in annual sales) of the top 14 pharma ceutical companies (see supplementary information s1 (box)). for the group overall, organic products — drugs that have been internally discovered and developed through to registration… Expand
4 Citations
Recent trends in specialty pharma business model.
  • M. S. Ku
  • Medicine
  • Journal of food and drug analysis
  • 2015
Drug dealers: $20 trillion of in-licensing payments.
The premium of a big pharma license deal